Link: Forests Phase III skin infection study meets study end point – Pharmaceutical Business Review.
Forest Laboratories has announced positive results from two globally conducted, multi-center Phase III studies of ceftaroline, a broad-spectrum cephalosporin with activity against gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus and gram negative bacteria, for the treatment of complicated skin and skin structure infections.
Print Article
Email A Friend
Your Comment
Post to del.icio.us
Digg this
Click here to find out more!RELATED ARTICLES
* Forest and Mylan amend Bystolica agreement
28 Feb 2008
* Glenmark receives milestone payment from Forest Labs
6 Feb 2008
* Forest and Daiichi terminate Azor co-promotion agreement
13 May 2008
* FDA issues approvable letter for nebivolol for hypertension
3 Dec 2007
* Caraco wins tentative FDA approval for generic Lexapro
3 Dec 2007COMPANIES MENTIONED
No companies found
WHITE PAPERS
No White Papers Available
Click here to find out more!The two globally conducted, multi-center, Phase III, randomized, double-blind comparative studies were designed to evaluate the efficacy and safety of ceftaroline compared to vancomycin plus aztreonam.
In both the studies, ceftaroline as monotherapy achieved the primary endpoint of non-inferiority versus the combination of vancomycin plus aztreonam. Ceftaroline treated patients had a clinical cure rate of 91.6% compared to a vancomycin plus aztreonam clinical cure rate of 92.7% at test-of-cure visit in the clinically evaluable population across both studies.
